Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib

Creative Commons License

Atilla P. A., Yalciner M., Atilla E., İDİLMAN R., BEKSAÇ M.

TURKISH JOURNAL OF HEMATOLOGY, cilt.36, sa.4, ss.266-273, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 36 Sayı: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.4274/tjh.galenos.2019.2019.0103
  • Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.266-273
  • Anahtar Kelimeler: Hepatitis B reactivation, Bortezomib, Lenalidomide, Multiple myeloma, Antiviral therapy, STEM-CELL TRANSPLANTATION, VIRUS REACTIVATION, LAMIVUDINE PROPHYLAXIS, HBV-CARRIERS, INFECTION, CHEMOTHERAPY, RISK, MANAGEMENT, MALIGNANCIES, ASSOCIATION
  • Ankara Üniversitesi Adresli: Evet

Özet

Objective: Reactivation of the hepatitis B virus (HBV) refers to an increase in HBV replication in a patient with inactive or resolved HBV. In this retrospective study, our aim is to present and compare HBV reactivation in multiple myeloma (MM) patients who received lenalidomide and/or bortezomib at any time during treatment, evaluate the factors associated with reactivation, and demonstrate the outcome of patients.